NZ196519A - Stable concentrated solutions of cisplatin - Google Patents

Stable concentrated solutions of cisplatin

Info

Publication number
NZ196519A
NZ196519A NZ196519A NZ19651981A NZ196519A NZ 196519 A NZ196519 A NZ 196519A NZ 196519 A NZ196519 A NZ 196519A NZ 19651981 A NZ19651981 A NZ 19651981A NZ 196519 A NZ196519 A NZ 196519A
Authority
NZ
New Zealand
Prior art keywords
cisplatin
concentrated solutions
stable concentrated
stable
solutions
Prior art date
Application number
NZ196519A
Other languages
English (en)
Inventor
M Kaplan
A Granatek
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NZ196519A publication Critical patent/NZ196519A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ196519A 1980-03-31 1981-03-17 Stable concentrated solutions of cisplatin NZ196519A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13537380A 1980-03-31 1980-03-31

Publications (1)

Publication Number Publication Date
NZ196519A true NZ196519A (en) 1983-06-17

Family

ID=22467813

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ196519A NZ196519A (en) 1980-03-31 1981-03-17 Stable concentrated solutions of cisplatin

Country Status (30)

Country Link
JP (1) JPS56152415A (es)
KR (1) KR860000841B1 (es)
AR (1) AR225500A1 (es)
AT (1) AT370996B (es)
AU (1) AU541056B2 (es)
BE (1) BE888209A (es)
CA (1) CA1162479A (es)
CH (1) CH647481A5 (es)
CS (1) CS246051B2 (es)
DD (1) DD157762A5 (es)
DE (1) DE3112272A1 (es)
DK (1) DK158564C (es)
ES (1) ES500869A0 (es)
FI (1) FI70670C (es)
FR (1) FR2480605A1 (es)
GB (1) GB2074028B (es)
GR (1) GR72769B (es)
HU (1) HU183379B (es)
IE (1) IE51070B1 (es)
IL (1) IL62517A (es)
IT (1) IT1170838B (es)
LU (1) LU83270A1 (es)
NL (1) NL8101531A (es)
NO (1) NO156675C (es)
NZ (1) NZ196519A (es)
PH (1) PH17152A (es)
PT (1) PT72774B (es)
SE (1) SE455045B (es)
SU (1) SU1056893A3 (es)
ZA (1) ZA812084B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
NL8303657A (nl) * 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
FI895340A0 (fi) * 1988-11-14 1989-11-09 Bristol Myers Squibb Co Hypertonisk cisplatin-loesning.
DE69725747T2 (de) * 1996-08-23 2004-07-29 Sequus Pharmaceuticals, Inc., Menlo Park Liposome enthaltend cisplatin
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
JP4445304B2 (ja) 2004-03-26 2010-04-07 オンキヨー株式会社 スイッチングアンプ
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
KR20200136997A (ko) 2018-03-29 2020-12-08 프로젝트 파마슈틱스 게엠베하 액체 약학적 제형

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
SE445172B (sv) * 1978-05-30 1986-06-09 Bristol Myers Co Stabil, steril vattenlosning av cisplatin i enhetsdoseringsform

Also Published As

Publication number Publication date
GB2074028A (en) 1981-10-28
BE888209A (fr) 1981-09-30
FR2480605B1 (es) 1984-05-11
DE3112272C2 (es) 1990-09-27
AR225500A1 (es) 1982-03-31
DK144281A (da) 1981-10-01
DD157762A5 (de) 1982-12-08
JPS6360008B2 (es) 1988-11-22
DK158564C (da) 1990-11-05
IE51070B1 (en) 1986-09-17
IE810715L (en) 1981-09-30
IL62517A (en) 1984-01-31
SU1056893A3 (ru) 1983-11-23
CA1162479A (en) 1984-02-21
DK158564B (da) 1990-06-11
ES8206545A1 (es) 1982-08-16
IL62517A0 (en) 1981-05-20
AU6816681A (en) 1981-10-08
AT370996B (de) 1983-05-25
CH647481A5 (fr) 1985-01-31
HU183379B (en) 1984-04-28
PT72774B (en) 1982-11-16
DE3112272A1 (de) 1982-04-29
PT72774A (en) 1981-04-01
GB2074028B (en) 1983-09-21
SE455045B (sv) 1988-06-20
ZA812084B (en) 1982-04-28
NO156675C (no) 1987-11-04
JPS56152415A (en) 1981-11-26
FI810934L (fi) 1981-10-01
KR830004849A (ko) 1983-07-20
FR2480605A1 (fr) 1981-10-23
PH17152A (en) 1984-06-13
ATA150481A (de) 1982-10-15
IT8148090A0 (it) 1981-03-24
FI70670C (fi) 1986-10-06
CS246051B2 (en) 1986-10-16
FI70670B (fi) 1986-06-26
IT1170838B (it) 1987-06-03
NL8101531A (nl) 1981-10-16
AU541056B2 (en) 1984-12-13
LU83270A1 (fr) 1981-10-29
KR860000841B1 (ko) 1986-07-09
NO156675B (no) 1987-07-27
GR72769B (es) 1983-12-02
SE8101990L (sv) 1981-11-13
ES500869A0 (es) 1982-08-16
NO811081L (no) 1981-10-01

Similar Documents

Publication Publication Date Title
JPS56128793A (en) Manufacture of hydrocarbylaldoside
JPS56143247A (en) 4-chlorothiazolyl containing compound
JPS56131590A (en) Manufacture of 3-iodomethylcephalosporins
JPS56103167A (en) Manufacture of azolyllvinylketone
GB2071665B (en) 18-glycyrrhizinic acid
JPS56120693A (en) Manufacture of dialkyldithiophosphinate
ZA813931B (en) Active compounds
GB2090738B (en) Suppository containing active ingredientcyclodextrin complex
GB2075539B (en) Stable highly concentrated colour former solutions
NZ196519A (en) Stable concentrated solutions of cisplatin
GB2018146B (en) Concentratint salt solutions
JPS56145956A (en) Direct manufacture of direct yellow-11 concentrated dye solution
ZA816885B (en) Oxygen blow-nozzle
JPS56145282A (en) Manufacture of 2-hydroxyalkylchroman
JPS56166185A (en) Manufacture of 2-hydroxytetrahydrofuran
JPS56150063A (en) Manufacture of n-hydroxyalkylcarbazole
JPS56142263A (en) Manufacture of hydrazono-isoindoline
JPS56145278A (en) Manufacture of dihalogentriazinyl-aminonaphthol- compound
JPS56169678A (en) Manufacture of 2-hydroxybenzothiazole
GB2035312B (en) Oxygen containing heterocyclics
GB2090594B (en) Fluoromethylthioacetic acid compounds
ZA812631B (en) Pharmaceologically active compounds
JPS56158736A (en) Manufacture of 4-trichloromethoxybenzoylchloride
JPS56104850A (en) Manufacture of 22aminoo44nitrophenol
CS227680B2 (en) Manufacture of 4-carbamoyloxyoxazaphosphorins